######## Fleming and Harrington #########
######## Ref. paper T. Hasegawa 2014 pharmaceutical statistics ##########
sample.size_FH <- function(
  eps, 
  p, 
  b, 
  tau, 
  omega,
  lambda,
  lambda.trt,
  rho, 
  gamma,
  alpha,
  beta
  ){
  # every sequence starts from 0
  # b<-30
  z.alpha <- qnorm(p = alpha, lower.tail = FALSE)
  z.beta <- qnorm(p = beta, lower.tail = FALSE)
  n_sub <- floor(b * tau)
  t <- c(0, seq(1, n_sub) / b)
  h_1 <- rep(lambda, (n_sub + 1)) #control
  h_2 <- c(
    rep(lambda, round(eps * b)),
    rep(lambda.trt, n_sub - round(eps * b) + 1)
    ) #treatment
  N_1 <- rep((1 - p),(n_sub + 1))
  N_2 <- rep(p, (n_sub + 1))
  for(i in 1:(n_sub-1)){
    N_1[i + 1] <- N_1[i] * (1 - h_1[i] / b - (t[i] > omega) / 
                            b / (tau - t[i]))
    N_2[i + 1] <- N_2[i] * (1 - h_2[i] / b-(t[i] > omega) / 
                              b / (tau - t[i]))
  }
  N_1[n_sub + 1] <- N_2[n_sub + 1] <- 0

  f_S_1 <- function(x) exp( - lambda * x)
  f_S_2 <- function(x) (x < eps) * exp( - lambda*x) + 
    (x >= eps) * exp( - (lambda * eps + lambda.trt * (x - eps)))
  #f_S_2_2<-function(x) (x<eps)*exp(-lambda*x)+(x>=eps)*exp(-eps*lambda.trt*(1/theta-1))*exp(-lambda.trt*x)
  S_1 <- f_S_1(t)
  S_2 <- f_S_2(t)
  S <- (1 - p) * S_1 + p * S_2
  D <- (h_1 * N_1 + h_2 * N_2) / b * min(tau / R, 1) 
  theta_seq <- h_2 / h_1
  phi <- N_2 / N_1
  r <- S^rho * (1 - S)^gamma
  num_vec <- D * r * (phi * theta_seq / (1 + phi * theta_seq) - 
                        phi / (1 + phi))
  den_vec <- D * r^2 * phi / (1 + phi)^2
  E.star_num <- sum(num_vec[1:n_sub])
  E.star_den <- sqrt(sum(den_vec[1:n_sub]))
  E.star <- E.star_num / E.star_den
  n <- (z.alpha + z.beta)^2 / E.star^2
  n_event <- sum(D) * n
  return(list(
    n = ceiling(ceiling(n * p) / p), 
    n_event = ceiling(ceiling(n_event*p)/p),
    E.star = E.star,
    sum_D = sum(D[1:n_sub]),
    D = D[1:n_sub],
    den_vec = den_vec[1:n_sub],
    num_vec = num_vec[1:n_sub],
    time_vec = seq(1, n_sub) / b))
}
if(F){
  # Example 1 in the paper Hasegawa(2014)
  p <- 2 / 3
  tau <- 66
  omega <- 18
  eps <- 6
  #theta<-0.79 #percent of full trt effect
  #lambda<-log(2)/6 # median survival time 10 months
  #lambda.trt<-lambda*theta #full treatment effect
  m1 <- 21.7
  m2 <- 25.8
  lambda <- log(2) / m1#log(2)/21.7 # median survival time 10 months
  lambda.trt <- log(2) * (m1 - eps) / (m2 - eps) / m1 #full treatment effect
  (theta <- lambda.trt / lambda)
  alpha <- 0.025
  beta <- 0.1
  rho <- 0
  gamma <- 1
  b <- 30
  res <- sample.size_FH(
    eps,
    p,
    b,
    tau,
    omega,
    lambda,
    lambda.trt,
    rho, 
    gamma,
    alpha,
    beta
    )
  length(res$den_vec)
  length(res$D)
}





#' The average hazard ratio calculation according to Hasegawa(2016) Phamaceutical Statistics paper
avg.haz <- function(theta, eps, lambda, p = 1 / 2){
  term1 <- 1 / 2 / p * (1 - exp(-2 * p * lambda * eps)) + 
    theta / p /(1 + theta) * exp( 
      - lambda * eps * (1 + p - theta * (1 - p))
      )
  term2 <- 1 / 2 / p * (1 - exp( - 2 * p * lambda * eps)) + 
    1 / p / (1 + theta) * exp(
      -lambda * eps * (1 + p - theta * (1 - p))
      )
  term1 / term2
}
# test
#lambda=log(2)/6
#theta=0.7
#eps=2
#avg.haz(theta,eps,lambda)
